



Universiteit
Leiden

The Netherlands

The value of rheumatoid arthritis autoantibodies in disease pathogenesis and treatment prognosis

Moel, E.C. de

Citation

Moel, E. C. de. (2026, April 7). *The value of rheumatoid arthritis autoantibodies in disease pathogenesis and treatment prognosis*. Retrieved from <https://hdl.handle.net/1887/4302760>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4302760>

Note: To cite this publication please use the final published version (if applicable).

The Value of Rheumatoid Arthritis Autoantibodies in Disease Pathogenesis and Treatment Prognosis

By Emma de Moel

Copyright 2026 E.C. de Moel, the Netherlands. All rights reserved. No part of this publication may be reproduced or transmitted in any form without permission of the copyright owner.

The research in this thesis was funded by the Dutch Research Council, ZonMw (the Netherlands Organisation for Health Research and Development; including the MODIRA consortium and a Veni grant), and Inova Diagnostics.

Provided by thesis specialist Ridderprint, ridderprint.nl

Printing: Ridderprint

Cover design: Emma de Moel

Layout and design: Indah Hijmans, persoonlijkproefschrift.nl

ISBN: 978-94-6537-316-4

The Value of Rheumatoid Arthritis Autoantibodies in Disease Pathogenesis and Treatment Prognosis

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector Mmgnificus prof.dr. S. de Rijcke,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 7 april 2026
klokke 14:30 uur

door

Emma de Moel

geboren te Zwolle

in 1991

Promotores

Prof. dr. D. van der Woude

Prof. dr. R.E.M. Toes

Leden promotiecommissie

Prof.dr. T.W.J. Huizinga

Prof. dr. A.H.M. van der Helm-van Mil

dr S.M. van der Kooij (HagaZiekenhuis)

dr K.A. Gelderman (Erasmus MC)

CONTENTS

Chapter 1	Introduction	7
Chapter 2	Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations	25
Chapter 3	Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes	47
Chapter 4	In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission	75
Chapter 5	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response	91
Chapter 6	Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs	111
Chapter 7	Autoantibody Development under Treatment with Immune Checkpoint Inhibitors	133
Chapter 8	Discussion	151
Appendices	<i>Nederlandse Samenvatting</i>	170
	<i>Curriculum vitae</i>	177
	<i>List of publications</i>	179
	<i>Dankwoord</i>	180